	US 12,343,365 B2
	Okra-derived antiviral composition and uses thereof
Anthony E. Archibong, Antioch, TN (US); Bindong Liu, Brentwood, TN (US); G. William Bates, Brentwood, TN (US); Elochukwu J. Ezekakpu, Nashville, TN (US); Lorin W. Simon, Antioch, TN (US); and James E. K. Hildreth, Nashville, TN (US)
Filed by Meharry Medical College, Nashville, TN (US)
Filed on Mar. 21, 2021, as Appl. No. 17/207,677.
Application 17/207,677 is a continuation of application No. PCT/US2019/051330, filed on Sep. 16, 2019.
Claims priority of provisional application 62/734,663, filed on Sep. 21, 2018.
Prior Publication US 2021/0228664 A1, Jul. 29, 2021
Int. Cl. A61K 36/185 (2006.01); A01N 1/02 (2006.01); A61B 17/43 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 36/185 (2013.01) [A01N 1/0221 (2013.01); A61B 17/43 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0036 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01); A61K 2236/331 (2013.01); A61K 2236/39 (2013.01); A61K 2236/53 (2013.01)]

10 Claims

1. A method of decreasing the endocytosis of a virus into a eukaryotic cell, the method comprising:

contacting the eukaryotic cell with an okra-derived composition in the presence of the virus, wherein the okra-derived composition is a product by process of extracting a fruit of okra and separating a substantially clear fluid from the extract;

wherein the eukaryotic cell is selected from the group consisting of dendritic cell, T cell, vaginal epithelial cell, cervical epithelial cell, uterine epithelial cell, and rectal epithelial cell, and

wherein the virus is selected from the group consisting of herpes simplex viruses, human papillomavirus, human immunodeficiency virus, hepatitis B virus and cytomegalovirus.